Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2012

View Archived Issues

U.S. university researchers disclose novel beta-amyloid production inhibitors

Pierre Fabre discloses new monoclonal antibodies for cancer

Novartis reflects on accomplishments of 2011

Novel phosphodiesterase 10A inhibitors prepared by Lundbeck

Merck KGaA patents new TGF-beta receptor type-1 inhibitors

Janssen Pharmaceutica synthesizes novel beta-secretase 1 inhibitors

Scientists at Cellzome patent novel TYK2 inhibitors

Histone deacetylase inhibitors may have potential in treating Gaucher's disease

Experiments delineate antiseizure activity of valpromide homolog

GenVec extends licensing and collaboration agreement with Novartis

Swissmedic grants marketing authorization for transdermal estradiol spray

Amgen enters definitive merger agreement

Cancer Research UK begins study of AT-9283

Indication for Gadovist 1.0 is expanded

FDA accepts bosutinib NDA for review

Infinity Pharmaceuticals completes preliminary analysis of saridegib/gemcitabine combination study

FDA approves axitinib for advanced renal cell carcinoma

Cell Therapeutics withdraws Pixuvri NDA

FDA approves first-ever once-weekly treatment for type 2 diabetes

European Commission requests further information in Glybera review

IDMC reviews Ziopharm's study of palifosfamide in metastatic soft tissue sarcoma

Amgen offers pipeline update for 2011

MT-110 shows promise in models of pancreatic cancer

Overseas trials begin for Pro-Rvlysin prostate cancer treatment

Navidea Biopharmaceuticals enters into agreement for Parkinson's disease imaging agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...